CG Oncology, Inc.
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 6, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 9 and 13 (est)
Price History
Beta
--
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
-- - --
52-week High
-- - --
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
949 409 3700
Address
3000 Pegasus Park Drive
Suite 1640
Dallas, TX 75247
Suite 1640
Dallas, TX 75247
Country
Year Founded
Business Description
Sector
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s...
more